Export 36 results:
Author Title Type [ Year(Asc)]
Filters: Author is Oden, Neal L  [Clear All Filters]
2023
I. U. Scott, Oden, N. L., VanVeldhuisen, P. C., Ip, M. S., and Blodi, B. A., “SCORE2 Report 20: Relationship of Treatment Discontinuation With Visual Acuity and Central Subfield Thickness Outcomes”, Am J Ophthalmol, vol. 248, pp. 157-163, 2023.
2022
I. U. Scott, Oden, N. L., VanVeldhuisen, P. C., Ip, M. S., and Blodi, B. A., “Baseline Characteristics and Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema in Participants with Hemiretinal Vein Occlusion Compared With Participants with Central Retinal Vein Occlusion (SCORE2) Report 18”, JAMA Ophthalmol, vol. 140, no. 5, pp. 458-464, 2022.
I. U. Scott, VanVeldhuisen, P. C., Oden, N. L., Ip, M. S., and Blodi, B. A., “Month 60 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion”, Am J Ophthalmol, vol. 240, pp. 330-341, 2022.
2021
R. N. Khurana, Oden, N. L., VanVeldhuisen, P. C., Scott, I. U., Blodi, B. A., and Ip, M. S., “Association between early and late response in eyes with central or hemiretinal vein occlusion treated with anti-VEGF agents : SCORE2 report 12: secondary analysis of the SCORE2 clinical trial.”, Graefes Arch Clin Exp Ophthalmol, vol. 239, no. 7, pp. 1839-1851, 2021.
A. A. Aref, Scott, I. U., VanVeldhuisen, P. C., King, J., Ip, M. S., Blodi, B. A., and Oden, N. L., “Intraocular Pressure-Related Events After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical Trial”, JAMA Ophthalmol, vol. 139, no. 12, pp. 1285-1291, 2021.
I. U. Scott, Oden, N. L., VanVeldhuisen, P. C., Ip, M. S., and Blodi, B. A., “SCORE2 Report 17: Macular Thickness Fluctuations in anti-VEGF-Treated Patients with Central or Hemiretinal Vein Occlusion”, Graefes Arch Clin Exp Ophthalmol, 2021.
2020
R. Khurana, Hendrick, A., Van Veldhuisen, P., Scott, I. U., Blodi, B. A., Ip, M. S., and Oden, N. L., “Change in Area of Intraretinal Macular Hemorrhages in Aflibercept- and Bevacizumab-treated Central Retinal and Hemiretinal Vein Occlusions: A SCORE2 Subanalysis”, in 43rd Annual Macula Society, San Diego, CA, 2020.
A. Hendrick, VanVeldhuisen, P. C., Scott, I. U., King, J., Blodi, B. A., Ip, M. S., Khurana, R. N., and Oden, N. L., “SCORE2 Report 13: Intraretinal Hemorrhage Changes in Eyes With Central or Hemiretinal Vein Occlusion Managed With Aflibercept, Bevacizumab or Observation. Secondary Analysis of the SCORE and SCORE2 Clinical Trials.”, Am J Ophthalmol, vol. 222, pp. 185-193, 2020.
2019
M. S. Ip, Oden, N. L., Scott, I. U., VanVeldhuisen, P. C., Blodi, B. A., Ghuman, T., and Baker, C. W., “Month 12 Outcomes After Treatment Change at Month 6 Among Poor Responders to Aflibercept or Bevacizumab in Eyes With Macular Edema Secondary to Central or Hemiretinal Vein Occlusion: A Secondary Analysis of the SCORE2 Study.”, JAMA Ophthalmol, vol. 137, no. 3, pp. 281-287, 2019.
I. U. Scott, Oden, N. L., VanVeldhuisen, P. C., Ip, M. S., Blodi, B. A., and Chan, C. K., “Month 24 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: SCORE2 Report 10: A Secondary Analysis of the SCORE2 Randomized Clinical Trial.”, JAMA Ophthalmol, 2019.
I. U. Scott, VanVeldhuisen, P. C., Barton, F., Oden, N. L., Ip, M. S., Blodi, B. A., Worrall, M., and Fish, G. E., “Patient-Reported Visual Function Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: Preplanned Secondary Analysis of a Randomized Clinical Trial.”, JAMA Ophthalmol, 2019.
2018
I. U. Scott, VanVeldhuisen, P. C., Ip, M. S., Blodi, B. A., Oden, N. L., Altaweel, M., and Berinstein, D. M., “Comparison of Monthly vs Treat-and-Extend Regimens for Individuals With Macular Edema Who Respond Well to Anti-Vascular Endothelial Growth Factor Medications: Secondary Outcomes From the SCORE2 Randomized Clinical Trial.”, JAMA Ophthalmol, vol. 136, no. 4, pp. 337-345, 2018.
2017
I. U. Scott, VanVeldhuisen, P. C., Ip, M. S., Blodi, B. A., Oden, N. L., King, J., Antoszyk, A. N., Peters, M. A., and Tolentino, M., “Baseline Factors Associated With 6-Month Visual Acuity and Retinal Thickness Outcomes in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Study Report 4.”, JAMA Ophthalmol, vol. 135, no. 6, pp. 639-649, 2017.
I. U. Scott, VanVeldhuisen, P. C., Ip, M. S., Blodi, B. A., Oden, N. L., Awh, C. C., Kunimoto, D. Y., Marcus, D. M., Wroblewski, J. J., and King, J., “Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial.”, JAMA, vol. 317, no. 20, pp. 2072-2087, 2017.
P. T. Korthuis, Lum, P. J., Vergara-Rodriguez, P., Ahamad, K., Wood, E., Kunkel, L. E., Oden, N. L., Lindblad, R., Sorensen, J. L., Arenas, V., Ha, D., Mandler, R. N., and McCarty, D., “Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial.”, Addiction, vol. 112, no. 6, pp. 1036-1044, 2017.
I. U. Scott, VanVeldhuisen, P. C., Ip, M. S., Blodi, B. A., Oden, N. L., Figueroa, M., and Dugel, P. U., “SCORE2 Report 2: Study Design and Baseline Characteristics.”, Ophthalmology, vol. 124, no. 2, pp. 245-256, 2017.
I. U. Scott, VanVeldhuisen, P. C., Ip, M. S., Blodi, B. A., Oden, N. L., Figueroa, M., and Dugel, P. U., “SCORE2 Report 2: Study Design and Baseline Characteristics.”, Ophthalmology, vol. 124, no. 2, pp. 245-256, 2017.
I. U. Scott, Figueroa, M. J., Oden, N. L., Ip, M. S., Blodi, B. A., and VanVeldhuisen, P. C., “SCORE2 Report 5: Vision-Related Function in Patients With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion.”, Am J Ophthalmol, vol. 184, pp. 147-156, 2017.
2016
I. U. Scott, VanVeldhuisen, P. C., Ip, M. S., Blodi, B. A., Oden, N. L., and Figueroa, M., “SCORE2 Report 1: Techniques to Optimize Recruitment in Phase III Clinical Trials of Patients With Central Retinal Vein Occlusion.”, Am J Ophthalmol, vol. 170, pp. 25-31, 2016.
2015
A. A. Aref, Scott, I. U., Oden, N. L., Ip, M. S., Blodi, B. A., and VanVeldhuisen, P. C., “Incidence, Risk Factors, and Timing of Elevated Intraocular Pressure After Intravitreal Triamcinolone Acetonide Injection for Macular Edema Secondary to Retinal Vein Occlusion: SCORE Study Report 15.”, JAMA Ophthalmol, vol. 133, no. 9, pp. 1022-9, 2015.
2014
M. P. Bogenschutz, Donovan, D. M., Mandler, R. N., Perl, H. I., Forcehimes, A. A., Crandall, C., Lindblad, R., Oden, N. L., Sharma, G., Metsch, L., Lyons, M. S., McCormack, R., Macias-Konstantopoulos, W., and Douaihy, A., “Brief intervention for patients with problematic drug use presenting in emergency departments: a randomized clinical trial.”, JAMA Intern Med, vol. 174, no. 11, pp. 1736-45, 2014.
2011
I. U. Scott, VanVeldhuisen, P. C., Oden, N. L., Ip, M. S., Blodi, B. A., Hartnett, M. Elizabeth, and Cohen, G., “Baseline predictors of visual acuity and retinal thickness outcomes in patients with retinal vein occlusion: Standard Care Versus COrticosteroid for REtinal Vein Occlusion Study report 10.”, Ophthalmology, vol. 118, no. 2, pp. 345-52, 2011.
M. P. Bogenschutz, Donovan, D. M., Adinoff, B., Crandall, C., Forcehimes, A. A., Lindblad, R., Mandler, R. N., Oden, N. L., Perl, H. I., and Walker, R., “Design of NIDA CTN Protocol 0047: screening, motivational assessment, referral, and treatment in emergency departments (SMART-ED).”, Am J Drug Alcohol Abuse, vol. 37, no. 5, pp. 417-25, 2011.
N. L. Oden, VanVeldhuisen, P. C., Wakim, P. G., Trivedi, M. H., Somoza, E., and Lewis, D., “Power of automated algorithms for combining time-line follow-back and urine drug screening test results in stimulant-abuse clinical trials.”, Am J Drug Alcohol Abuse, vol. 37, no. 5, pp. 350-7, 2011.
C. K. Chan, Ip, M. S., VanVeldhuisen, P. C., Oden, N. L., Scott, I. U., Tolentino, M. J., and Blodi, B. A., “SCORE Study report #11: incidences of neovascular events in eyes with retinal vein occlusion.”, Ophthalmology, vol. 118, no. 7, pp. 1364-72, 2011.